LDLR Antibodies

Structure of LDLR

The low-density lipoprotein receptor encoded by the LDLR gene is a type I transmembrane protein with a molecular weight of approximately 160 kDa. The molecular weight of this protein varies among different species, mainly due to the variation in the number of repetitive sequences in its ligand-binding domain.

This receptor consists of five major domains: The ligand-binding domain at the N-terminal contains seven cysteine-rich repeat sequences, which are responsible for specifically recognizing apolipoprotein B-100; The homologous domain of epidermal growth factor precursors is involved in receptor recycling. O-linked sugar domains provide structural support; Transmembrane domains are anchored to the cell membrane; And the cytoplasmic domain at the C-terminal contains NPxY internalization signals, mediating the endocytosis process of reticin-coated pits.

Fig. 1 Schematic of full-length LDLR and its truncated mutants (ΔLBD, ΔEGF).¹

Key structural properties of LDLR:

• Modular multi-domain configuration
• Cysteine-rich ligands bind repeat sequences
• Epidermal growth factor (EGF) precursor homeodomain
• Intracellular domain NPxY motifs

Functions of LDLR

The core function of the LDLR gene-encoded protein is to maintain cholesterol homeostasis, and its specific functions cover the following aspects:

This receptor shows high affinity and saturation for LDL uptake, and its functional activity is strictly feedback inhibited by cellular cholesterol levels. This precise regulatory mechanism is crucial for maintaining the balance of lipid metabolism in the body.

Applications of LDLR and LDLR Antibody in Literature

1. Xu, Zhi-Sheng, et al. "LDLR is an entry receptor for Crimean-Congo hemorrhagic fever virus." Cell research 34.2 (2024): 140-150. https://doi.org/10.1038/s41422-023-00917-w

This study found that the low-density lipoprotein receptor (LDLR) is the key receptor for the Crimean-Congo hemorrhagic fever virus (CCHFV) to enter host cells. Viruses mediate infection through the binding of their glycoprotein Gc to LDLR. Blocking this receptor can significantly inhibit viral infection, providing a new strategy for the treatment of this disease.

2. Meshkov, Alexey, et al. "The LDLR, APOB, and PCSK9 variants of index patients with familial hypercholesterolemia in Russia." Genes 12.1 (2021): 66. https://doi.org/10.3390/genes12010066

Research has found that the low-density lipoprotein receptor (LDLR) is a key receptor for the Crimean-Congo hemorrhagic fever virus (CCHFV) to invade cells. Viruses bind to LDLR through their Gc proteins. Blocking this receptor can effectively inhibit infection, providing a new target for treatment.

3. Li, Zhelong, et al. "Exosome-based Ldlr gene therapy for familial hypercholesterolemia in a mouse model." Theranostics 11.6 (2021): 2953. https://www.thno.org/v11p2953.htm

Researchers successfully restored the expression of low-density lipoprotein receptors (LDLR) by delivering Ldlr mRNA to the livers of mice with LDLR gene deletion using exosomes. This therapy effectively reduced blood lipids and atherosclerotic plaques, providing a new strategy for the treatment of familial hypercholesterolemia (FH).

4. Yuan, Juanjuan, et al. "Correction to: Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling." Protein & Cell 13.9 (2022): 694-700. https://doi.org/10.1007/s13238-021-00833-y

Research has found that low-density lipoprotein receptors (LDLR) play a key role in the anti-tumor activity of CD8+ T cells. It not only assists in cholesterol intake but also regulates the TCR cycle and signal transduction by interacting with the TCR complex. PCSK9 in the tumor microenvironment degrades LDLR, thereby inhibiting T cell function, which provides a new target for cancer immunotherapy.

5. Galicia-Garcia, Unai, et al. "Mutation type classification and pathogenicity assignment of sixteen missense variants located in the EGF-precursor homology domain of the LDLR." Scientific Reports 10.1 (2020): 1727. https://doi.org/10.1038/s41598-020-58734-9

This study focuses on the pathogenic gene LDLR of familial hypercholesterolemia (FH), and particularly analyzes 16 genetic variations in the homologous domain of its EGF precursor. The study classified these variations into non-pathogenic and pathogenic ones through functional experiments. The latter can be further divided into categories such as functional impairment, transport defect and recovery abnormality, providing an important basis for clinical diagnosis and treatment intensity.

Creative Biolabs: LDLR Antibodies for Research

Creative Biolabs specializes in the production of high-quality LDLR antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom LDLR Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our LDLR antibodies, custom preparations, or technical support, contact us at email.